Chen, Xiaoying
Li, Cheryl
Ewesuedo, Reginald
Yin, Donghua
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
https://doi.org/10.1007/s40259-021-00513-7
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
https://doi.org/10.1007/s00280-019-03850-1
Article History
Received: 29 March 2019
Accepted: 25 April 2019
First Online: 3 May 2019
Change Date: 10 July 2019
Change Type: Correction
Change Details: The article “Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin<Superscript>®</Superscript>) in patients with HER2-positive metastatic breast cancer” written by Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 3rd May 2019 without open access.
Compliance with ethical standards
:
: XC, CL, RE, and DY are employees of and hold stock in Pfizer Inc.
: All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.